Autolus Therapeutics (AUTL) to Cut Workforce by 13% While Doubling 2026 Manufacturing Capacity

Autolus Therapeutics (NASDAQ:AUTL) is one of the best fast growing penny stocks to buy right now. On April 29, Autolus launched a strategic initiative to improve operational efficiency and accelerate its path to profitability for the acute lymphoblastic leukemia/ALL business. As part of this plan, the company will reduce its workforce by ~13%, a move expected to save $15 million annually starting in 2027. Despite these cuts, Autolus plans to double its manufacturing capacity for commercial and clinical products in 2026 to support growing demand.

The company reaffirmed its 2026 financial guidance for AUCATZYL, projecting net product revenue between $120 million and $135 million, nearly double the previous year’s figures. Management also anticipates a shift to a positive gross margin this year, driven by strong commercial momentum. Restructuring charges of approximately $8 million are expected to be recognized mostly in H1 2026, with the reorganization largely completed by Q3.

Autolus Therapeutics (AUTL) to Cut Workforce by 13% While Doubling 2026 Manufacturing Capacity

Photo by National Cancer Institute on Unsplash

Clinical development remains on track across several key programs, including pivotal trials for pediatric leukemia and lupus nephritis, as well as exploratory work in multiple sclerosis. Current cash reserves are projected to fund operations into Q4 2027. CEO Dr. Christian Itin emphasized that while the workforce reduction is difficult, the focus remains on optimizing the operating model and delivering long-term value to stockholders.

Autolus Therapeutics (NASDAQ:AUTL) develops T cell therapies for cancer and autoimmune diseases in the United Kingdom and internationally.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.